Ares Financial Consulting’s Rhythm Pharmaceuticals RYTM Stock Holding History

Ares Financial Consulting’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$555	Buy	+5	New	+$452	﹤0.01%	1082

Other funds holding RYTM

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Aspiriant LLC Los Angeles, California $4.05B AUM 19.01% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

KOCAA

Knights of Columbus Asset Advisors New Haven, Connecticut $2B AUM 42.86% 1-Year Est. Return

Ares Financial Consulting's RYTM Position: Q2 2026 in Review

Ares Financial Consulting opened a new position in Rhythm Pharmaceuticals (RYTM) in Q2 2026: 5 shares worth $555. The stake represents ﹤0.01% of the portfolio and ranks #1082 among its holdings.

70 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Ares Financial Consulting held 5 shares of Rhythm Pharmaceuticals worth $555 as of Q2 2026.
Rhythm Pharmaceuticals was a new Ares Financial Consulting position in Q2 2026.
Rhythm Pharmaceuticals made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #1082 holding.
70 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.